drugset / Trial / NCT03175497
Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors
Phase 1
Completed
15 enrolled
Taizhou EOC Pharma Co., Ltd.
Fountain Medical Development Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this China Phase I bridging study is to to evaluate the safety, tolerability and pharmacokinetic profile of telatinib in China patients with advanced solid tumor
Timeline
- Start
- 2017-07-25
- Primary completion
- 2018-08-15
- Completion
- 2018-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telatinib | Small molecule | 600 mg | Oral |
| Subject | Telatinib | Small molecule | 900 mg | Oral |
| Subject | Telatinib | Small molecule | 1200 mg | Oral |